Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pegylated interferon-α

pegylated interferon-α

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of pegylated interferon-α

6 trials tracked of pegylated interferon-α.

6Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 4 Phase 1 1 Other / NA 1
  1. Phase 2 Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B Completed
  2. Phase 2 A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028) Completed
  3. Phase 2 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Completed
  4. Phase 2 Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders Completed
  5. Phase 1 Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients Completed
  6. N/A Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562) Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
PEG-IFN plus novel agents may boost functional cure in chronic hepatitis B
Infectious Disease Sys. Review
PEG-IFN plus novel agents may boost functional cure in chronic hepatitis B Combination therapies may improve functional cure rates for chronic hepatitis B
This narrative review examines combining pegylated interferon-α with novel immunotherapies (antigen-reduction strategies, therapeutic vaccin…
A review suggests combining pegylated interferon with new immunotherapies could help achieve functional cure in chronic hepatitis B patients…
Frontiers Jun 6, 2026
Pegylated interferon-alpha toxicity mechanisms and management in chronic hepatitis B patients
Urology Sys. Review
Pegylated interferon-alpha toxicity mechanisms and management in chronic hepatitis B patients New Way to Handle Painful Side Effects of Hepatitis B Drug
This systematic review examined mechanisms and management of pegylated interferon-alpha toxicity in patients with chronic hepatitis B.
A powerful hepatitis B drug can cause severe flu-like symptoms and other painful reactions, but new strategies aim to manage these side effe…
Frontiers Apr 11, 2026